These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 25087979)
1. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Tremblay AM; Missiaglia E; Galli GG; Hettmer S; Urcia R; Carrara M; Judson RN; Thway K; Nadal G; Selfe JL; Murray G; Calogero RA; De Bari C; Zammit PS; Delorenzi M; Wagers AJ; Shipley J; Wackerhage H; Camargo FD Cancer Cell; 2014 Aug; 26(2):273-87. PubMed ID: 25087979 [TBL] [Abstract][Full Text] [Related]
2. YAPping about differentiation therapy in muscle cancer. Svalina MN; Keller C Cancer Cell; 2014 Aug; 26(2):154-5. PubMed ID: 25117705 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma. Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028 [TBL] [Abstract][Full Text] [Related]
4. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927 [TBL] [Abstract][Full Text] [Related]
5. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. Rivera-Reyes A; Ye S; E Marino G; Egolf S; E Ciotti G; Chor S; Liu Y; Posimo JM; Park PMC; Pak K; Babichev Y; Sostre-Colón J; Tameire F; Leli NM; Koumenis C; C Brady D; Mancuso A; Weber K; Gladdy R; Qi J; Eisinger-Mathason TSK Cell Death Dis; 2018 Oct; 9(11):1108. PubMed ID: 30382078 [TBL] [Abstract][Full Text] [Related]
6. CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG. Liu Z; Zhang X; Lei H; Lam N; Carter S; Yockey O; Xu M; Mendoza A; Hernandez ER; Wei JS; Khan J; Yohe ME; Shern JF; Thiele CJ Nat Commun; 2020 Feb; 11(1):911. PubMed ID: 32060262 [TBL] [Abstract][Full Text] [Related]
7. YAP1-TEAD1 signaling controls angiogenesis and mitochondrial biogenesis through PGC1α. Mammoto A; Muyleart M; Kadlec A; Gutterman D; Mammoto T Microvasc Res; 2018 Sep; 119():73-83. PubMed ID: 29680477 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Belyea BC; Naini S; Bentley RC; Linardic CM Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088 [TBL] [Abstract][Full Text] [Related]
9. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Ota M; Sasaki H Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856 [TBL] [Abstract][Full Text] [Related]
10. Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma. Slemmons KK; Yeung C; Baumgart JT; Juarez JOM; McCalla A; Helman LJ Cancer Res; 2020 Jul; 80(14):3046-3056. PubMed ID: 32354737 [TBL] [Abstract][Full Text] [Related]
11. A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma. Slemmons KK; Crose LES; Riedel S; Sushnitha M; Belyea B; Linardic CM Mol Cancer Res; 2017 Dec; 15(12):1777-1791. PubMed ID: 28923841 [TBL] [Abstract][Full Text] [Related]
14. YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. Lin C; Xu X Biomed Pharmacother; 2017 Nov; 95():789-794. PubMed ID: 28892790 [TBL] [Abstract][Full Text] [Related]
15. YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Kim M; Ly SH; Xie Y; Duronio GN; Ford-Roshon D; Hwang JH; Sulahian R; Rennhack JP; So J; Gjoerup O; Talamas JA; Grandclaudon M; Long HW; Doench JG; Sethi NS; Giannakis M; Hahn WC Dev Cell; 2022 Jan; 57(2):212-227.e8. PubMed ID: 34990589 [TBL] [Abstract][Full Text] [Related]